DCM
EPRX

Delaney Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Delaney Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$768K Sell
117,200
-2,200
-2% -$15.2K 0.12% 38
2026
Q1 		$860K Hold
119,400
– – 0.14% 36
2025
Q4 		$899K Buy
+119,400
New +$736K 0.15% 32

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Delaney Capital Management's EPRX Position: Q2 2026 in Review

Delaney Capital Management reduced its Eupraxia Pharmaceuticals (EPRX) stake by 1.8% in Q2 2026, selling an estimated $15.2K and leaving 117,200 shares worth $768K. The position accounts for 0.12% of the portfolio, ranked #38.

Delaney Capital Management first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $899K in Q4 2025. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Delaney Capital Management held 117,200 shares of Eupraxia Pharmaceuticals worth $768K as of Q2 2026.
  • Delaney Capital Management sold 2,200 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $15.2K.
  • Eupraxia Pharmaceuticals made up 0.12% of Delaney Capital Management's portfolio in Q2 2026, its #38 holding.
  • Delaney Capital Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Delaney Capital Management's Eupraxia Pharmaceuticals position peaked at $899K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Delaney Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.